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Abstract: The two organic anion transporting polypeptides (OATPs) 1B1 and 1B3 are expressed at the sinusoidal mem-
brane of hepatocytes. They have a broad and overlapping substrate specificity and transport many endobiotics and drugs. 
Specific inhibitors are required to determine the contribution of each OATP to the hepatocellular uptake of common sub-
strates. We have developed a cell-based high-throughput assay to screen chemical libraries in order to identify such in-
hibitors for OATP1B1 and OATP1B3. We have used OATP1B1- or OATP1B3-expressing Chinese Hamster Ovary cells 
on 96-well plates and determined uptake of fluorescein-methotrexate (FMTX). We validated the assay with known inhibi-
tors and screened the well characterized Prestwick library of 1120 drugs. Along with several known OATP inhibitors in-
cluding rifampicin, cyclosporine A and mifepristone we identified some new inhibitors. For inhibitors that seemed to be 
able to distinguish between OATP1B1- and OATP1B3-mediated FMTX uptake IC50 values were determined. Estropipate 
(estrone-3-sulfate stabilized with piperazine) was the most selective OATP1B1 inhibitor (IC50 = 0.06 μM vs. 19.3 μM for 
OATP1B3). Ursolic acid was the most selective OATP1B3 inhibitor (IC50 = 2.3 μM vs. 12.5 μM for OATP1B1). In  
conclusion, this cell-based assay should allow us to identify even more specific inhibitors by screening larger chemical  
libraries. 
Keywords: OATP1B1, OATP1B3, fluorescein-methotrexate, cell based assay, high-throughput screening. 
INTRODUCTION 
  Organic anion transporting polypeptides (humans: 
OATPs; rodents: Oatps) form a large gene superfamily of 
transport proteins expressed in multiple organs [1, 2]. Many 
of their members are multispecific transporters that mediate 
the uptake of numerous endo- and xeno-biotics. Human 
OATP1B1 and OATP1B3 are expressed in the sinusoidal 
membrane of hepatocytes and are thought to be liver-specific 
under normal physiological conditions. They are responsible 
for the uptake of numerous drugs, including statins, endo-
thelin receptor antagonists, anticancer drugs like 
methotrexate and paclitaxel, as well as the antibiotic rifam-
picin [1]. Besides specific substrates like prostaglandin E2 
for OATP1B1 and CCK-8 for OATP1B3 [3, 4], OATP1B1 
and OATP1B3 have a number of common drug substrates 
including bosentan [5], fluvastatin [6], methotrexate [7, 8], 
olmesartan [9], pitavastatin [10], rifampicin [11], rosuvasta-
tin [12], and valsartan [13]. Given that both OATPs are ex-
pressed in human hepatocytes, it will be almost impossible 
without specific inhibitors to elucidate which of the two pro-
teins is more important for the transport of a certain drug. 
Furthermore, these transporters can affect the bioavailability  
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of drugs. In 1996 we demonstrated that the peptide-based 
thrombin inhibitor CRC 220 is a substrate of rat Oatp1a1 
[14]. This explained the very high hepatic first pass elimina-
tion of CRC 220 which was partially responsible for its low 
bioavailability. Specific OATP1B1 or OATP1B3 inhibitors 
could be co-applied with a drug which is efficiently cleared 
by the liver and this could increase its bioavailability.  
  In order to identify potentially specific inhibitors for 
OATP1B1 and OATP1B3, we decided to develop an assay 
for high-throughput screening. Fluorescent substrates are 
preferred for high-throughput screening because of the sensi-
tivity and dynamic range that the fluorescence signal affords. 
So far only fluorescent bile acids [15] and Fluo-3, a fluores-
cent calcium indicator [16, 17] have been demonstrated to be 
substrates for OATP1B3 while fluorescein methotrexate 
(FMTX) has been reported as a substrate for OATP1B1 [18]. 
However, methotrexate has been shown to be a substrate for 
both OATP1B1 and OATP1B3 [8] and is commercially 
available as fluorescein methotrexate (FMTX) and Alexa 
Fluor® 488 methotrexate (AMTX). Preliminary data from 
our laboratory also demonstrated that the anticancer drug 
paclitaxel is a substrate for both OATPs. A fluorescent ver-
sion of paclitaxel is also available commercially as Oregon 
Green® 488 Taxol (Flutax-2). Therefore, we compared these 
different fluorescent compounds along with fluorescein as 
substrates for OATP1B1 and OATP1B3. We further charac-
terized FMTX transport by both OATPs and established an 
assay on 96-well plates for high-throughput screening. We 2    Current Chemical Genomics, 2010, Volume 4  Gui et al. 
used this assay to screen the Prestwick library for modulators 
(inhibitors or stimulators) and confirmed several hits by 
measuring IC50 or EC50 values for inhibition and stimulation 
of OATP1B1- and OATP1B3-mediated FMTX transport.  
MATERIALS AND METHODS 
Materials 
  Cell culture reagents, fluorescein-methotrexate (FMTX), 
Alexa Fluor® 488 methotrexate (AMTX), and Oregon 
Green® 488 Taxol (Flutax-2) were purchased from Invitro-
gen (Carlsbad, CA). Fetal bovine serum was from Hyclone 
(Logan, UT). The Prestwick library was obtained from the 
University of Kansas High Throughput Screening Labora-
tory. Individual chemicals for the confirmatory experiments 
were either from Prestwick Chemical or from Sigma and 
stock solutions were prepared in DMSO.  
Cell Culture and Transport Assay on 24-well Plates  
  Chinese Hamster Ovary (CHO) cells stably expressing 
OATP1B1 and OATP1B3 were described previously [19] 
and were grown at 37 °C in a humidified 5% CO2 atmos-
phere in Dulbecco’s Modified Eagle Medium, containing 1 
g/l D-glucose, 2 mM L-glutamine, 25 mM Hepes buffer and 
110 mg/l sodium pyruvate, supplemented with 10% FBS 
(Hyclone, Logan, UT), 50 g/ml L-proline, 100 U/ml peni-
cillin and 100 g/ml streptomycin, and 500 μg/ml G-418. 
Cells were passaged twice a week and used up to passage 55. 
Protein concentrations were very consistent, both on 24-well 
plates (0.150 ± 0.005 mg/well) as well as on 96-well plates 
(0.045 ± 0.002 mg/well). Transport assays on 24-well plates 
were performed as described [19] with the following modifi-
cations: cells were washed three times with 1 ml of pre-
warmed (37 °C) uptake buffer (116.4 mM NaCl, 5.3 mM 
KCl, 1 mM NaH2PO4, 0.8 mM MgSO4, 5.5 mM D-glucose 
and 20 mM Hepes, pH adjusted to 7.4 with Trizma base) and 
uptake was started by adding 200 l of uptake buffer con-
taining the indicated concentrations of fluorescent com-
pound. After the indicated time period at 37 °C, uptake was 
stopped by removing the uptake solution and washing the 
cells four times with 1 ml of ice-cold uptake buffer. The cell 
membranes were then disrupted with 300 l of 1% Triton X-
100 (dissolved in PBS) and fluorescence was measured in a 
Bio-Tek Synergy HT microplate reader (Winooski, VT) at 
an excitation wavelength of 485 nm and an emission wave-
length of 528 nm. 
High-Throughput Uptake Experiments in 96-well Plates 
  For high-throughput uptake experiments, OATP-
expressing CHO cells were plated at 12,000 cells per well on 
96-well plates and 48 hours later medium was replaced with 
medium containing 5 mM Na-butyrate to induce nonspecific 
gene expression. Previous experiments with OATP express-
ing CHO cells have demonstrated that after treatment of 
CHO cells with Na-butyrate transporter function was in-
creased due to an increase in the maximal transport rate [20]. 
After another 24 hours in culture, the cells were used for 
uptake experiments. Cells were washed three times with 200 
l of room temperature uptake buffer (116.4 mM NaCl, 5.3 
m M  KC l,  1  mM  N a H 2PO4, 0.8 mM MgSO4, 5.5 mM D-
glucose and 20 mM Hepes, pH adjusted to 7.4 with Trizma 
base) and uptake was started by adding 70 l of uptake 
buffer containing 5 M substrate in the presence or absence 
of inhibitors. After 30 min culture at room temperature, up-
take was stopped by removing the uptake solution and wash-
ing the cells four times with 200 μl of room temperature up-
take buffer. The cells were then solubilized with 100 l of 
1% Triton X-100 (dissolved in PBS). Fluorescence was 
measured in a Bio-Tek Synergy HT microplate reader (Wi-
nooski, VT) at an excitation wavelength of 485 nm and an 
emission wavelength of 528 nm. 
Data Analysis 
  Z’ factor calculation and assay validation were done ac-
cording to NIH assay guidance manual [21]. The data were 
analyzed using Sigmaplot and Graphpad prism. Statistical 
significance was determined using the two-tailed unpaired 
Student’s t test. 
RESULTS 
Characterization of Fluorescent Substrate Transport by 
OATP1B1 and OATP1B3 
  In the first set of experiments, we compared the uptake of 
four new fluorescent compounds, fluorescein-methotrexate 
(FMTX), Alexa Fluor® 488 methotrexate (AMTX), Oregon 
Green® 488 Taxol (Flutax-2) and fluorescein to the uptake 
of the known OATP substrate Fluo-3. As can be seen in Fig. 
(1), four of the five compounds namely Fluo-3, FMTX, Flu-
tax-2 and fluorescein are substrates for OATP1B3, while 
AMTX was not transported. OATP1B1 on the other hand 
only transported FMTX and fluorescein. Given that radiola-
beled methotrexate has previously been documented as a 
substrate for both OATP1B1 and OATP1B3 [8] and that the 
uptake signal for both OATP1B3 (about 4.5 fold) and 
OATP1B1 (about 3 fold) was highest for FMTX, we decided 
to further characterize it. As the results in Fig. (2) demon-
strate, uptake of 10 μM FMTX was linear over a 5 min pe-
riod. Thus, we used the 2 min time point to determine the 
kinetic parameters of OATP-mediated FMTX transport. Fig. 
(3) shows one of three independent experiments and demon-
 
 
 
 
 
 
 
 
 
 
Fig. (1). Comparison of OATP1B1- and OATP1B3-mediated trans-
port of fluorescent substrates. Uptake was measured with 1 μM of 
the indicated fluorescent compounds on 24-well plates for 30 min. 
Values are means ± SE of two combined independent experiments 
each performed with triplicate determinations. FMTX: fluorescein 
methotrexate; AMTX: Alexa Fluor® 488 methotrexate; Flutax-2: 
Oregon Green® 488 Taxol; WT: wild-type CHO cells; OATP1B1: 
CHO cells expressing OATP1B1; OATP1B3: CHO cells 
expressing OATP1B3.  
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strates that OATP1B3 (closed circles) has a much higher 
capacity than OATP1B1 (open circles) to transport FMTX. 
Based on all three experiments we calculated for OATP1B1 
an apparent Km value of 3.8 ± 0.7 μM and a Vmax value of 
961  ± 198 fluorescent units/mg protein * min and for 
OATP1B3 an apparent Km value of 7.9 ± 2.0 μM and a Vmax 
value of 4772 ± 709 fluorescent units/mg protein * min. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Time dependent uptake of FMTX into CHO cells express-
ing OATP1B1 and OATP1B3. Uptake of 10 μM FMTX was de-
termined at 37 °C with wild-type (closed triangles), OATP1B1 
(open circles) or OATP1B3 (closed circles) expressing CHO cells 
on 24-well plates. Values are means ± SE of quadruplicate determi-
nations in a single experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Kinetics of OATP1B1- and OATP1B3-mediated FMTX 
uptake. Uptake of increasing concentrations of FMTX was meas-
ured at 37 °C for 2 min on 24-well plates with CHO wild-type and 
OATP1B1 or OATP1B3 expressing cells. Net OATP1B1 (open 
circles) or OATP1B3 (closed circles) uptake was calculated by 
subtracting uptake into wild-type cells from uptake into OATP-
expressing cells. The values (means ± SE) were fitted to the Micha-
elis-Menten equation using non-linear regression analysis. 
 
Establishing a High-Throughput Assay on 96-well Plates 
  In order to test whether this cell-based assay could be run 
on 96-well plates instead of on 24-well plates, we deter-
mined uptake of 5 μM FMTX in the absence or presence of 
known OATP substrates or inhibitors for 30 min at room 
temperature on 96-well plates. We could detect FMTX up-
take mediated by both OATPs. A typical uptake resulted in 
4,400 ± 80 fluorescent units for wild-type CHO cells, 15,060 
± 1,540 fluorescent units for OATP1B1-expressing cells and 
33,880 ± 3,645 fluorescent units for OATP1B3-expressing 
cells. Thus, signal-to-basal ratios of 3.4 for OATP1B1 and of 
7.7 for OATP1B3 were obtained. As can be seen from Fig. 
(4), uptake by OATP1B1 and OATP1B3 was inhibited by all 
tested compounds. In additional experiments (data not 
shown), we determined that uptake at room temperature was 
linear over at least 30 min. Furthermore, we calculated the Z’ 
factors for the assays (0.26 for OATP1B1 and 0.46 for 
OATP1B3) in the absence (negative control) and presence 
(positive control) of 10 μM rifampicin with three independ-
ent 96-well plates. Validation was performed following the 
recommendations of the NIH assay guidance manual [21]. 
The coefficient of variance for all maximal signals, unnor-
malized middle signals and minimal signals was less than 
20%. Furthermore, all minimal signal standard deviations 
were smaller than both, the standard deviations of the middle 
and the maximal signals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Inhibition of OATP-mediated FMTX uptake by known 
inhibitors/substrates. Uptake of 5 μM FMTX was measured for 30 
min at room temperature on 96-well plates with OATP-expressing 
and wild-type CHO cells in the absence or presence of the indicated 
compounds. Values obtained with wild-type CHO cells were sub-
tracted from values obtained with OATP-expressing cells and are 
given as percent of control. Means ± SE of two combined inde-
pendent experiments each performed with quadruplicate determina-
tions are shown. * p < 0.05; E3S: estrone-3-sulfate; E17G: estra-
diol-17-glucuronide. 
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Screening of Prestwick Library 
  To screen the 1120 compounds in the Prestwick library, 
we included 8 wells of negative (DMSO controls) and 8 
wells of positive (10 μM rifampicin in DMSO) controls in 
each plate. As can be seen from the screening statistics 
shown in Table 1, we have developed a useful assay to 
screen for OATP1B3 inhibitors but the assay needs to be 
improved to be used with OATP1B1. Z’ values for the 
OATP1B1 part were close to zero or even negative, while 
the values for the OATP1B3 part were between 0.41 and 
0.79. Nevertheless, we identify inhibitors for both OATP1B1 
and OATP1B3 mediated uptake and a stimulator for 
OATP1B3. Among the strongest inhibitors found were 
known OATP substrates and/or inhibitors like cyclosporine 
A, rifampicin, saquinavir and several statins. In addition to 
these compounds, several new substances were found to in-
hibit FMTX transport mediated by either OATP1B1 or 
OATP1B3 or by both. 
  To confirm these hits of the screening results, we deter-
mined IC50 values for several compounds that preferentially 
inhibited either OATP1B1 or OATP1B3 or seemed to stimu-
late one or the other OATP. Among the tested compounds 
we identified five compounds that inhibited OATP1B1 more 
potently than OATP1B3 and three that preferentially inhib-
ited OATP1B3 mediated FMTX transport (Table 2, Fig. 5). 
Estropipate, which is estrone-sulfate stabilized with 
piperazine, was the strongest OATP1B1 inhibitor with an 
IC50 of 0.06 ± 0.01 μM, while it hardly inhibited OATP1B3 
at concentrations up to 1 μM (IC50 of 19.3 ± 6.3 μM) (Table 
2). In addition to estropipate, we found that bromocryptine, 
ergocryptine, fipexide, niflumic acid and repaglinide prefer-
entially inhibited OATP1B1 (Table 2, Fig. 5), while 
beclamethasone, moricizine and ursolic acid preferentially 
inhibited OATP1B3 (Table 2, Fig. 5). Among the potential 
stimulators we could confirm that progesterone stimulated 
OATP1B3-mediated FMTX uptake with an EC50 of 0.2 μM, 
while it inhibited OATP1B1-mediated FMTX uptake with an 
IC50 of 5.4 ± 1.9 μM (Fig. 6).  
DISCUSSION 
  In this study, we established a good high-throughput as-
say for OATP1B3 (Z’ factor > 0.4) that allows screening for 
inhibitors and stimulators of OATP1B3. The assay estab-
lished for OATP1B1 needs more optimization perhaps using 
a different substrate to be as valuable as the one for 
OATP1B3. Initially we tested several fluorescent com-
pounds as potential substrates for OATP1B1 and OATP1B3 
and compared them to the known OATP1B1 and OATP1B3 
substrate Fluo-3 [16, 17, 19]. Because fluorescein-
methotrexate (FMTX) resulted in the highest signal for both 
OATP1B1 and OATP1B3 and because radiolabeled 
Table 1.  Statistics of Prestwick Library Screening 
O A T P 1 B 1                   
Plate  number  1 2 3 4 5 6 7 8 9  10  11  12  13  14 
Mean (neg 
control) 
5,170 5,906 5,428 7,400 6,166 4,984 4,866 6,113 5,670 6,713 6,390 6,054 6,042  9,159 
STDEV (neg 
control) 
390  1,107  807 924 579 645 451 721 634  1,150  425 605 444  921 
Mean (pos 
control) 
9,411 10,044 9,499 14,100  10,904 9,080  8,950 11,267  10,641  11,879  12,990  12,183  14,967  16,572 
STDEV (pos 
control) 
871  715  753 1,520  1,267 803  537 1,042 935 1,663 954 1,226  1,249  1,760 
Sample  mean  9,654 10,381 9,101 13,350 9,857  8,448  8,967 11,136  10,397  11,423  12,343  11,735  12,785  16,997 
Z'  factor  0.11 -0.32  -0.15 -0.09 -0.17  -0.06 0.27 -0.03 0.05 -0.63 0.37 0.10 0.43  -0.08 
O A T P 1 B 3                   
Plate  number  1 2 3 4 5 6 7 8 9  10  11  12  13  14 
Mean (neg 
control) 
7,161 8,034 7,766  10,591  7,901 7,506 7,734 9,639 8,273 8,231 8,418 9,093 9,047  9,856 
STDEV (neg 
control) 
760 1,315  1,037  1,814 523  834 1,194  1,495 761  332  370  472  570  1,026 
Mean (pos 
control) 
26,768 31,694 27,097 31,987 28,351 25,272 30,369 26,319 26,882 30,781 31,653 34,132 34,603  32,986 
STDEV (pos 
control) 
1,704 2,889 1,778 1,212 1,789 2,271 2,257 1,792 1,171 4,063 1,281 3,003 3,917  3,014 
Sample  mean  26,308 26,850 23,819 33,715 26,838 25,368 25,738 29,565 26,661 29,799 29,365 33,188 31,714  36,503 
Z'  factor   0.62 0.47 0.56 0.58 0.66 0.48 0.54 0.41 0.69 0.42 0.79 0.58  0.47  0.48 High-Throughput Assay for OATP1B1 and OATP1B3 Transporters  Current Chemical Genomics, 2010, Volume 4    5 
Table 2.  Inhibition of OATP1B1- and OATP1B3-Mediated Fluorescein-Methotrexate (FMTX) Uptake by Prestwick Library Com-
pounds 
Compound IC50 on OATP1B1 (μM) IC50 on OATP1B3 (μM) 
2-aminobenzenesulfonamide  > 100  > 100 
Aconitine  > 100  No inhibition 
Beclomethasone  6.7 ± 1.2  1.4 ± 0.4 
Bromocryptine  0.7 ± 0.08  1.8 ± 0.3 
Captopril  No inhibition  No inhibition 
Ergocryptine  0.8 ± 0.2  2.2 ± 1.2 
Estropipate  0.06 ± 0.01  19.3 ± 6.3 
Etomidate  > 100  > 100 
Fipexide  34.5 ± 6.8  > 100 
Metronidazole  > 100  > 100 
Moricizine  8.1 ± 1.9  2.7 ± 0.4 
Niflumic acid  3.7 ± 1.4  22.0 ± 6.8 
Ramipril  4.0 ± 0.5  3.3 ± 0.3 
Repaglinide  1.1 ± 0.2  4.8 ± 0.7 
Resveratrol  11.2 ± 2.0  23.7 ± 2.5 
Rifampicin  1.3 ± 0.2  1.5 ± 0.5 
Trifluridine  No inhibition  No inhibition 
Ursolic acid  12.5 ± 1.9  2.3 ± 0.03 
Results are means ± SE of at least three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Inhibition of OATP-mediated FMTX uptake by selected Prestwick compounds. Concentration dependent inhibition of 5 μM FMTX 
by indicated compounds was measured for 30 min at room temperature on 96-well plates with wild-type and OATP-expressing CHO cells. 
Values obtained with wild-type CHO cells were subtracted from values obtained with OATP-expressing cells and are given as percent of 
control. Means ± SE of the means of three independent experiments are shown and were used to calculate IC50 values.  6    Current Chemical Genomics, 2010, Volume 4  Gui et al. 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Effect of progesterone on OATP1B1- and OATP1B3-mediated FMTX uptake. Concentration dependent inhibition of OATP1B1-
mediated and stimulation of OATP1B3-mediated 5 μM FMTX uptake was measured for 30 min at room temperature on 96-well plates with 
wild-type and OATP-expressing CHO cells. Values obtained with wild-type CHO cells were subtracted from values obtained with OATP-
expressing cells and are given as percent of control. Means ± SE of two combined independent experiments each performed in quadruplicates 
are shown and were used to calculate IC50 and EC50 values, respectively. 
methotrexate has previously been identified as a substrate for 
both OATP1B1 and OATP1B3 [8], we decided to continue 
with this substrate and further characterize its transport. Our 
results show that FMTX is transported by both OATPs (Figs. 
1,  2 and 3) and the kinetic parameters suggest that 
OATP1B3 has a 2–3 fold higher efficiency (Vmax/Km = 604) 
than OATP1B1 (Vmax/Km = 252) to transport FMTX. This is 
similar to the transport of Fluo-3 which is also transported 
much better by OATP1B3 than by OATP1B1 [19], suggest-
ing that the fluorescent moiety might be more important for 
recognition of FMTX by these two OATPs than the 
methotrexate moiety. This hypothesis is further supported by 
the finding that inhibition of OATP1B1-mediated pitavas-
tatin uptake by methotrexate was very weak (Ki > 300 μM) 
[22] and by our own observations that methotrexate at 100 
μM only inhibited OATP-mediated FMTX uptake by 30% 
(data not shown). Therefore, it is likely that additional fluo-
rescein-conjugates are transported by OATP1B1 and 
OATP1B3. Along the same lines, we also tested fluorescein 
itself and found that it is indeed a substrate for both trans-
porters. However, the apparent affinity constants were about 
10 fold higher for fluorescein (Km OATP1B1 38 ± 5 μM; Km 
OATP1B3 82 ± 10 μM) than for FMTX (Km OATP1B1 3.8 
± 0.7 μM; Km OATP1B3 7.9 ± 2.0 μM), suggesting that 
FMTX is the better substrate and that more than just the 
fluorescein moiety of the FMTX molecule is recognized by 
the transporters.  
  After having established that FMTX is a substrate for 
both OATP1B1 and OATP1B3, we tested the transport assay 
on 96-well plates at room temperature which would allow us 
to perform high-throughput screening. There was clear up-
take signal for OATP1B1 and OATP1B3 (3.5 fold for 
OATP1B1 and 7.7 fold for OATP1B3) which could be in-
hibited by several common OATP substrates (Fig. 4).  
  Although the Z’ factors were not very high (0.26 for 
OATP1B1 and 0.46 for OATP1B3), we screened the Prest-
wick library and observed several hits for both OATPs. The 
screening statistics (Table 1) confirmed that the assay is very 
useful with respect to OATP1B3 but needs improvement for 
OATP1B1. We are currently testing additional fluorescent 
compounds as substrates, in particular for OATP1B1, in or-
der to increase the signal and establish a reliable assay also 
for OATP1B1. In the follow-up experiments, we determined 
IC50 values for several inhibitors identified by the primary 
screening for the inhibition of 5 μM FMTX transported by 
either OATP. Some of the compounds that seemed to be 
stimulators during the primary screening could not be con-
firmed as stimulators, but inhibited slightly at higher concen-
trations and are listed with IC50 values larger than 100 μM 
(2-aminobenxenesulfonamide, aconitine, etomidate, metron-
idazole and trifluridine). The only stimulator that could be 
confirmed was progesterone which stimulated OATP1B3-
mediated transport but inhibited OATP1B1-mediated trans-
port. Progesterone has previously been shown to also stimu-
late OATP2B1- mediated estrone-3-sulfate uptake [23]. 
  Rifampicin which inhibited FMTX uptake of both 
OATPs with an IC50 of 1.3 to 1.5 M (Table 2) has previ-
ously been shown to be an inhibitor and substrate for both 
OATPs [11] and has since been used to characterize OATP 
mediated transport by many groups. However, inhibition by 
rifampicin is dependent on the transported substrate. 
Fexofenadine has been inhibited by rifampicin with Ki val-
ues of 0.5 M for OATP1B1 and of 1.5 M for OATP1B3 
[24] while BSP was inhibited with Ki values of 17 M for 
OATP1B1 and 5 M for OATP1B3 [11]. Treiber et al. [5] 
reported inhibition of bosentan transport with IC50 values of 
3.2 M for OATP1B1 and 1.6 M for OATP1B3 while up-
take of the bosentan metabolite Ro 48-5033 was inhibited 
with IC50 values of about 50 M for OATP1B1 and 0.8 M 
for OATP1B3. These data clearly demonstrate substrate de-
pendent inhibition patterns for OATP1B1 and OATP1B3-
mediated transport. Previously, IC50 values between 0.9 and 
1.5  M for inhibition of OATP1B1 and 2.6 M for 
OATP1B3 mediated estradiol-17-glucuronide have been 
reported [19, 25]. These values are in good agreement with 
the values obtained in this study with FMTX and could indi-
cate that estradiol-17-glucuronide and FMTX are handled 
by the transporters in a very similar way while bosentan and 
its metabolite are probably transported via a different sub-
strate binding site or translocation pathway given that the 
inhibition affinities are reversed. Based on the same assump-
tions it can be concluded that BSP and FMTX are probably 
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handled in a very similar way given that IC50 values of repa-
glinide inhibition for OATP1B1 and OATP1B3 obtained in 
this study are very similar to the ones obtained with BSP as a 
substrate [26]. Thus, the results of this study confirm that it 
is important to keep in mind that multispecific transporters 
like OATP1B1 and OATP1B3 seem to have multiple over-
lapping substrate binding/transport sites that are also affected 
by inhibitors in a substrate dependent way.  
  Estropipate (estrone-sulfate stabilized with piperazine) 
was the only compound among the real inhibitors that can be 
considered selective for OATP1B1-mediated FMTX trans-
port. It inhibited OATP1B1 with an IC50 value of 0.06 μM, 
while the IC50 value for OATP1B3-mediated FMTX trans-
port was approximately 320-fold higher (Table 2). Besides 
indocyanine green which has been shown to be a specific 
inhibitor for OATP1B1-mediated estradiol-17-glucuronide 
transport while not affecting OATP1B3-mediated estradiol-
17-glucuronide transport at concentrations up to 10 μM 
[27], estropipate is as far as we know the only other selective 
inhibitor that inhibits OATP1B1 with hardly any effect on 
OATP1B3 at concentrations up to 1 μM at which concentra-
tion it completely inhibits OATP1B1 (Fig. 5). The most se-
lective OATP1B3 inhibitors we identified were ursolic acid 
and beclomethasone that were about 5-fold more selective 
for OATP1B3 than for OATP1B1, but they were not as se-
lective as the two OATP1B3 selective inhibitors T-3095 and 
T-3157 [28]. 
  In conclusion, we have established that FMTX is a sub-
strate for OATP1B1 and OATP1B3 and that it can be used 
for high-throughput screening with OATP1B3. Using this 
assay we have identified estropipate as a selective inhibitor 
for OATP1B1-mediated FMTX transport, and ursolic acid 
and beclomethasone as preferential inhibitors for OATP1B3-
mediated FMTX transport. To identify additional more spe-
cific OATP1B1 and OATP1B3 inhibitors, we are currently 
improving the assay especially for OATP1B1 and then plan 
to extend the screening to larger libraries that are available at 
the High Throughput Laboratory of the University of Kan-
sas. 
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